• Теги
    • избранные теги
    • Компании1837
      • Показать ещё
      Разное695
      • Показать ещё
      Международные организации74
      • Показать ещё
      Страны / Регионы692
      • Показать ещё
      Формат24
      Показатели24
      • Показать ещё
      Издания83
      • Показать ещё
      Люди68
      • Показать ещё
      Сферы4
21 июля, 15:49

GlaxoSmithKline's new CEO prepares to trim drug pipeline

GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.

21 июля, 01:19

Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

20 июля, 18:12

What Lies in Store for Glaxo (GSK) this Earnings Season?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

Выбор редакции
19 июля, 17:51

GlaxoSmithKline to sell UK Horlicks brand and scrap factory plans

Company will close Slough plant where malt drink is made and axe proposed Cumbria factory with loss of about 320 jobsGlaxoSmithKline has unveiled plans to sell its Horlicks brand in the UK, shut the Slough plant where the malt drink is made and abandon a proposed £350m biopharmaceutical manufacturing plant in Cumbria.The planned factory at Ulverston was hailed five years ago as a boost to Cumbria by the then prime minister, David Cameron, but in a major blow to the area GSK says it no longer needs the extra capacity. It may also sell its antibiotics business at Ulverston, which produces brands such as Zinnat, Zinacef and Fortum. Continue reading...

Выбор редакции
19 июля, 16:12

GlaxoSmithKline to cut 320 U.K. jobs over next 4 years

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

19 июля, 01:10

Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval

Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.

15 июля, 11:00

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

14 июля, 21:35

Gilead (GILD) Application for HIV Drug Validated in EU

Gilead Sciences, Inc. (GILD) announced that the company's Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency.

07 июля, 16:30

Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

07 июля, 15:25

Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

Выбор редакции
05 июля, 15:47

Threat to HIV business spooks GlaxoSmithKline shares

The threat of slowing demand and new competition in GlaxoSmithKline's (GSK.L) flagship HIV drug business unnerved investors in Britain's biggest drugmaker on Wednesday, sending its shares down as much as 1.8 percent. GSK pared losses to 0.8 percent by 1220 GMT but remained among the top losers in London's FTSE-100 index after Citigroup downgraded the stock to neutral from buy and cut earnings forecasts by up to 9 percent. HIV medicines, which GSK sells through its ViiV Healthcare unit, have been star performers in recent years and new CEO Emma Walmsley said in April that the "HIV portfolio continues to go from strength to strength".

Выбор редакции
02 июля, 19:01

Big pharma turns to AI to speed up tests, cut costs

The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new US$43 million deal in the field

02 июля, 03:43

Big pharma turns to AI to speed drug discovery, GSK signs deal

LONDON (Reuters) - The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday.

Выбор редакции
30 июня, 17:46

Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

29 июня, 16:54

Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

28 июня, 16:26

Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

27 июня, 20:53

Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike

Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike

26 июня, 16:00

Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

14 мая 2014, 18:13

Китай обвинил британского менеджера GlaxoSmithKline в даче взяток - economy

Китайская полиция предъявила обвинения в даче взяток бывшему руководителю китайского подразделения британской фармацевтической компании GlaxoSmithKline. Пекин заявляет, что Марк Рейли, возглавлявший бизнес в Китае с 2009 года, и два китайских менеджера организовали коррупционную сеть: персонал GSK подкупал врачей за продвижение лекарств фирмы, благодаря чему продажи выросли на сотни миллионов евро. Сумма взяток оценивается китайской полицией в 400 млн евро. Дело GSK - крупнейший в Китае корруп... ЧИТАТЬ ДАЛЕЕ: http://ru.euronews.com/2014/05/14/glaxosmithkline-bosses-in-china-charged-with-bribery Последние новости смотрите здесь: http://eurone.ws/1hfoGvh euronews: самый популярный новостной канал в Европе. Подписывайтесь! http://eurone.ws/ZdZ0Zo euronews доступен на 14 языках: http://eurone.ws/11ILlKF На русском: Сайт: http://ru.euronews.com Facebook: http://www.facebook.com/euronews Twitter: http://twitter.com/euronewsru Google+: http://eurone.ws/1eEChLr VKontakte: http://vk.com/ru.euronews